George Karpouzas
Rheumatology · Torrance, CANPI 1154384303
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $130,793 of the $155,438 with a category attached, or 84.1%. Janssen Research & Development, LLC accounts for 72.1% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2023 at $58,681 and has fallen 99.6% since, to $219 in 2025. Among rheumatology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 113 payments — averaging $1375.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$112K
- Sanofi$17K
- Regeneron Healthcare Solutions, Inc.$13K
- Johnson & Johnson$6K
- E.r. Squibb & Sons, L.L.C.$6K
- Bristol Myers Squibb$342
- plus $913 from 9 others
Across 155 payments — averaging $6552.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$303K
- AbbVie$302K
- Amgen$172K
- E.r. Squibb & Sons, L.L.C.$111K
- GSK$53K
- Aurinia Pharma U.S., Inc.$38K
- plus $36K from 2 others
What the payments were for
- Consulting fees$130,79384%
- Speaking & faculty fees$18,23612%
- Travel & lodging$4,3523%
- Food & beverage$1,5451%
- Education$5120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 11 | $112,000 |
| Sanofi | 17 | $17,493 |
| Regeneron Healthcare Solutions, Inc. | 26 | $12,673 |
| Johnson & Johnson(2 entities) | 13 | $6,245 |
| E.r. Squibb & Sons, L.L.C. | 7 | $5,772 |
| Bristol Myers Squibb | 2 | $342 |
| AbbVie | 11 | $219 |
| Amgen | 7 | $192 |
| Pfizer | 8 | $140 |
| Mallinckrodt Enterprises LLC | 5 | $134 |
| Genentech, Inc. | 2 | $107 |
| Janssen Scientific Affairs, LLC | 1 | $45 |
| AstraZeneca | 1 | $31 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| GSK | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$155,438 in reported general payments places this provider in the 90th percentile of 808 rheumatology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxychloroquine Sulfate | 11 | $640 |
| MethotrexateMethotrexate Sodium | 13 | $595 |
| Azathioprine | 12 | $473 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Torrance
- Sudhakar TumuluriSan Francisco$2.8M
- Ara DikranianSan Diego$2.2M
- Orrin TroumSanta Monica$1.8M
- Robin DoreTustin$1.5M
- Samy MetyasCovina$1.3M
- Rhonda LambertSan Mateo$1.1M
- William ShielMission Viejo$924K
- Mark BoriginiDowney$920K
- Adam KreitenbergTarzana$863K
- Roger KornuTustin$802K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.